Literature DB >> 10769174

Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites.

Z L Woodman1, S Y Oppong, S Cook, N M Hooper, S L Schwager, W F Brandt, M R Ehlers, E D Sturrock.   

Abstract

The somatic and testis isoforms of angiotensin-converting enzyme (ACE) are both C-terminally anchored ectoproteins that are shed by an unidentified secretase. Although testis and somatic ACE both share the same stalk and membrane domains the latter was reported to be shed inefficiently compared with testis ACE, and this was ascribed to cleavage at an alternative site [Beldent, Michaud, Bonnefoy, Chauvet and Corvol (1995) J. Biol. Chem. 270, 28962-28969]. These differences constitute a useful model system of the regulation and substrate preferences of the ACE secretase, and hence we investigated this further. In transfected Chinese hamster ovary cells, human somatic ACE (hsACE) was indeed shed less efficiently than human testis ACE, and shedding of somatic ACE responded poorly to phorbol ester activation. However, using several analytical techniques, we found no evidence that the somatic ACE cleavage site differed from that characterized in testis ACE. First, anti-peptide antibodies raised to specific sequences on either side of the reported cleavage site (Arg(1137)/Leu(1138)) clearly recognized soluble porcine somatic ACE, indicating that cleavage was C-terminal to Arg(1137). Second, a competitive ELISA gave superimposable curves for porcine plasma ACE, secretase-cleaved porcine somatic ACE (eACE), and trypsin-cleaved ACE, suggesting similar C-terminal sequences. Third, mass-spectral analyses of digests of released soluble hsACE or of eACE enabled precise assignments of the C-termini, in each case to Arg(1203). These data indicated that soluble human and porcine somatic ACE, whether generated in vivo or in vitro, have C-termini consistent with cleavage at a single site, the Arg(1203)/Ser(1204) bond, identical with the Arg(627)/Ser(628) site in testis ACE. In conclusion, the inefficient release of somatic ACE is not due to cleavage at an alternative stalk site, but instead supports the hypothesis that the testis ACE ectodomain contains a motif that activates shedding, which is occluded by the additional domain found in somatic ACE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769174      PMCID: PMC1221007     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

Review 1.  Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins.

Authors:  M R Ehlers; J F Riordan
Journal:  Biochemistry       Date:  1991-10-22       Impact factor: 3.162

2.  Purification and characterization of recombinant human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells.

Authors:  M R Ehlers; Y N Chen; J F Riordan
Journal:  Protein Expr Purif       Date:  1991-02       Impact factor: 1.650

3.  Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site.

Authors:  V Beldent; A Michaud; L Wei; M T Chauvet; P Corvol
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

4.  Use of antipeptide antibodies for the isolation and study of membrane proteins.

Authors:  S A Baldwin
Journal:  Methods Mol Biol       Date:  1994

5.  Regulated cleavage-secretion of the membrane-bound angiotensin-converting enzyme.

Authors:  R Ramchandran; G C Sen; K Misono; I Sen
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes.

Authors:  L Wei; F Alhenc-Gelas; F Soubrier; A Michaud; P Corvol; E Clauser
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

7.  A comparison of the zinc contents and substrate specificities of the endothelial and testicular forms of porcine angiotensin converting enzyme and the preparation of isoenzyme-specific antisera.

Authors:  T A Williams; K Barnes; A J Kenny; A J Turner; N M Hooper
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

8.  Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane.

Authors:  S Y Oppong; N M Hooper
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

9.  The two homologous domains of human angiotensin I-converting enzyme are both catalytically active.

Authors:  L Wei; F Alhenc-Gelas; P Corvol; E Clauser
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

10.  The unique N-terminal sequence of testis angiotensin-converting enzyme is heavily O-glycosylated and unessential for activity or stability.

Authors:  M R Ehlers; Y N Chen; J F Riordan
Journal:  Biochem Biophys Res Commun       Date:  1992-02-28       Impact factor: 3.575

View more
  20 in total

1.  Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor.

Authors:  Matthew L Hemming; Dennis J Selkoe
Journal:  J Biol Chem       Date:  2005-09-09       Impact factor: 5.157

2.  The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity.

Authors:  Zenda L Woodman; Sylva L U Schwager; Pierre Redelinghuys; Adriana K Carmona; Mario R W Ehlers; Edward D Sturrock
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

3.  Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding.

Authors:  S Pang; A J Chubb; S L Schwager; M R Ehlers; E D Sturrock; N M Hooper
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

4.  Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface.

Authors:  Irina V Balyasnikova; Eric H Karran; Ronald F Albrecht; Sergei M Danilov
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

Review 5.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

6.  Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.

Authors:  Gillian I Rice; Daniel A Thomas; Peter J Grant; Anthony J Turner; Nigel M Hooper
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

7.  Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia.

Authors:  Hong Peng Jia; Dwight C Look; Ping Tan; Lei Shi; Melissa Hickey; Lokesh Gakhar; Mark C Chappell; Christine Wohlford-Lenane; Paul B McCray
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-01       Impact factor: 5.464

8.  The influence of mouse Ped gene expression on postnatal development.

Authors:  Adam Watkins; Adrian Wilkins; Clive Osmond; Carol M Warner; Martina Comiskey; Mark Hanson; Tom P Fleming
Journal:  J Physiol       Date:  2005-11-03       Impact factor: 5.182

9.  A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor.

Authors:  Alexandre Persu; Michel Lambert; Jaap Deinum; Marta Cossu; Nathalie de Visscher; Leonid Irenge; Jerôme Ambroise; Jean-Marc Minon; Andrew B Nesterovitch; Alexander Churbanov; Isolda A Popova; Sergei M Danilov; A H Jan Danser; Jean-Luc Gala
Journal:  PLoS One       Date:  2013-04-01       Impact factor: 3.240

10.  Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE.

Authors:  Andrew B Nesterovitch; Kyle D Hogarth; Vyacheslav A Adarichev; Elena I Vinokour; David E Schwartz; Julian Solway; Sergei M Danilov
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.